UNSPSC 51161560: Nisbuterol

This classification denotes an anti-asthmatic agent with the molecular formula C22H27NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NKL13V61JH, chemically known as [2-acetyloxy-4-[2-(tert-butylamino)-1-hydroxyethyl]phenyl]4-methoxybenzoate but generally known as nisbuterol, which bears US NIH Compound Identifier 3047793. European Medicines Agency schedules nisbuterol its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09305MIG. Most nations schedule nisbuterol under HS 29225000 and SITC 51467.

As of Q4 2014, NISBUTEROL remains the US FDA Preferred Term for this commodity. Nisbuterol bears US NLM identifiers UMLS ID C2983896 and NCI Concept Code C90819. SMILES: CC(=O)OC1=C(C=CC(=C1)C(CNC(C)(C)C)O)OC(=O)C2=CC=C(C=C2)OC.

UNSPSC 51161560 Nisbuterol, a Commodity code, covers pharmaceutical products being solicited by state and local cooperative purchasing alliances and participating government facilities to support clinical and operational needs across multiple jurisdictions. The work entails supplying branded and generic pharmaceutical products meeting FDA requirements, cGMP certification, and Drug Supply Chain Security Act compliance, with vendors establishing pricing and distribution through authorized pharmaceutical wholesalers and demonstrating EDI capability, insurance coverage (including $5,000,000 commercial general liability per occurrence), and contractual relationships with at least two of three designated wholesaler partners. State and local buyers under this code include cooperative purchasing organizations such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which pools demand across participating state agencies, local governments, and healthcare facilities in multiple states including Oregon. Vendors must maintain comprehensive product documentation by National Drug Code (NDC), stock keeping unit (SKU), and packaging configuration, with all products available in the marketplace and maintaining minimum six-month shelf life and one-year expiration dates from manufacture.

The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued a Request for Proposal (S1070000015802) on January 20, 2026, seeking manufacturers and distributors of generic multi-source pharmaceuticals and over-the-counter products with a response due date of March 26, 2026 and a question cutoff of February 18, 2026. The awarded vendors will be provided to authorized wholesalers (AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) by May 15, 2026, with resulting contracts effective July 1, 2026. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Contract terms span two years for new responders with optional extensions, while incumbent amendments extend through June 30, 2028. MMCAP reserves discretion for sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.